Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Inclusion Criteria:

1. Completed the 12-week treatment period in 1 of the 2 parent studies (StudyDMVT-505-3001 or Study DMVT-505-3002);
2. Male and female subjects
3. Females of child bearing potential and male subjects who are engaging in sexualactivity that could lead to pregnancy agree to follow the specified contraceptiveguidance while on the study, and for at least 4 weeks after the last exposure to studytreatment
4. Capable of giving written informed consent

Exclusion Criteria:

1. Used a prohibited concomitant product or procedure to treat psoriasis during parentstudy
2. Had a serious adverse event (SAE) that was potentially related to treatment orexperienced an adverse event (AE) that led to permanent discontinuation of treatmentin the parent study
3. History of or ongoing serious illness or medical, physical, or psychiatriccondition(s) that, in the Investigator's opinion, may interfere with the subject'scompletion of the study
4. Known hypersensitivity to tapinarof